Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto James Conant, president of Harvard University and chairman of the National Defense Research Committee (NDRC). They urged Thomas to become co-director of the Manhattan Project at Los Alamos with Robert Oppenheimer, but Thomas was reluctant to leave Dayton and Monsanto. He joined the NDRC, and Monsanto's Central Research Department began to conduct related research. To that end, Monsanto operated the Dayton Project, and later Mound Laboratories, and assisted in the development of the first nuclear weapons. In 1946, Monsanto developed and marketed "All" laundry detergent, which they sold to Lever Brothers in 1957. In 1947, its styrene factory was destroyed